Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York, USA.
Mol Pharmacol. 2012 Sep;82(3):438-47. doi: 10.1124/mol.112.078501. Epub 2012 May 31.
Metabotropic glutamate receptors (mGluRs) were thought until recently to function mainly as stable homodimers, but recent work suggests that heteromerization is possible. Despite the growth in available compounds targeting mGluRs, little is known about the pharmacological profile of mGluR heterodimers. Here, this question was addressed for the mGluR2/4 heterodimer, examined by coexpressing both receptors in isolated sympathetic neurons from the rat superior cervical ganglion (SCG), a native neuronal system with a null mGluR background. Under conditions that favor mGluR2/4 heterodimer formation, activation of the receptor was not evident with the mGluR2-selective agonist (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV) or with the mGluR4 selective agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4); however, full activation was apparent when both ligands were applied together, confirming that mGluR dimers require ligand binding in both subunits for full activation. Properties of allosteric modulators were also examined, including the findings that negative allosteric modulators (NAMs) have two binding sites per dimer and that positive allosteric modulators (PAMs) have only a single site per dimer. In SCG neurons, mGluR2/4 dimers were not inhibited by the mGluR2-selective NAM (Z)-1-[2-cycloheptyloxy-2-(2,6-dichlorophenyl)ethenyl]-1H-1,2,4-triazole (Ro 64-5229), supporting the two-site model. Furthermore, application of the mGluR4 selective PAMs N-(4-chloro-3-methoxyphenyl)-2-pyridinecarboxamide (VU0361737) or N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) and combined application of mGluR4 PAMs with the mGluR2 selective PAM biphenyl indanone-A failed to potentiate glutamate responses through mGluR2/4, suggesting that mGluR2/4 heterodimers are not modulatable by PAMs that are currently available.
代谢型谷氨酸受体(mGluRs)直到最近还被认为主要作为稳定的同二聚体发挥作用,但最近的研究表明异源二聚体化是可能的。尽管针对 mGluRs 的化合物数量不断增加,但对 mGluR 异源二聚体的药理学特征知之甚少。在这里,通过在大鼠颈上神经节(SCG)的分离交感神经元中共同表达这两种受体,检查了 mGluR2/4 异源二聚体的这个问题,这是一个具有 mGluR 背景的天然神经元系统。在有利于 mGluR2/4 异源二聚体形成的条件下,用 mGluR2 选择性激动剂(2S,2'R,3'R)-2-(2',3'-二羧基环丙基)甘氨酸(DCG-IV)或 mGluR4 选择性激动剂 L-(+)-2-氨基-4-膦酸丁酸(L-AP4)激活受体并不明显;然而,当两种配体一起应用时,完全激活是明显的,这证实 mGluR 二聚体需要两个亚基中的配体结合才能完全激活。还检查了变构调节剂的性质,包括发现负变构调节剂(NAMs)每个二聚体有两个结合位点,而正变构调节剂(PAMs)每个二聚体只有一个位点。在 SCG 神经元中,mGluR2/4 二聚体不受 mGluR2 选择性 NAM(Z)-1-[2-环庚氧基-2-(2,6-二氯苯基)乙烯基]-1H-1,2,4-三唑(Ro 64-5229)抑制,支持双位点模型。此外,应用 mGluR4 选择性 PAMs N-(4-氯-3-甲氧基苯基)-2-吡啶甲酰胺(VU0361737)或 N-苯基-7-(羟亚氨基)环丙[a]苯并吡喃-1a-羧酰胺(PHCCC)以及 mGluR4 PAMs 与 mGluR2 选择性 PAM 联苯茚酮-A 的联合应用未能通过 mGluR2/4 增强谷氨酸反应,这表明目前可用的 PAMs 不能调节 mGluR2/4 异源二聚体。